ArticleParasites & vectors2025
Efficacy of Credelio Quattro
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHaemaphysalis longicornis, the longhorned tick, is an invasive tick species that has been identified in increasing numbers and regions across the USA. This tick species is a competent vector for various pathogens to dogs, humans, and other species, with heavy infestations documented to lead to exsanguination. Therefore, determination of ectoparasiticides providing adequate treatment and control of H. longicornis is imperative to help reduce vector-borne disease transmission and protect against infestation in dogs.
methodsThree laboratory studies were conducted to evaluate the efficacy of Credelio Quattro and Credelio for the treatment and control of H. longicornis. A total of 30 dogs per study were randomized to receive either placebo, Credelio Quattro, or Credelio on Day 0 according to a complete block design on the basis of pre-treatment live attached H. longicornis counts, infested on Day -7. To assess efficacy against preexisting infestations, enrolled dogs were infested with 50 unfed adult H. longicornis on Day -2 or -1 prior to treatment. Residual efficacy post-treatment was evaluated with subsequent infestations on Days 5, 12, 19, and 30. All ticks were collected and evaluated as live or dead and free or attached 48 h after treatment or infestation.
resultsAdequacy of infestation was achieved in at least two studies for every infestation time point evaluated. Both Credelio Quattro and Credelio provided 100% efficacy against H. longicornis from Day 2 through Day 32, with no live ticks observed on any dogs. A statistically significant number of dead ticks were recovered from both treated groups as compared with control on all assessment days. Post-treatment, treatment-related diarrhea was reported in six dogs receiving Credelio Quattro and one dog receiving Credelio on Day 0, with all dogs recovering on Day 1.
conclusionsThe laboratory studies described confirm the safety and effectiveness of a single dose of Credelio Quattro and Credelio, at the minimum effective dosage of 20 mg/kg lotilaner, 0.02 mg/kg moxidectin, 5 mg/kg praziquantel, 5 mg/kg pyrantel, and 20 mg/kg lotilaner, respectively, for the treatment and control of H. longicornis infestations in dogs for one month.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.